<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Bio Briefing - Countermeasures: Anthrax]]></title><link>http://www.upmc-biosecurity.org/</link><description><![CDATA[Biosecurity Briefing articles relating to anthrax countermeasure developments.]]></description><copyright><![CDATA[Copyright 2010. University of Pittsburgh Medical Center. All rights reserved.]]></copyright><managingEditor><![CDATA[webmaster@umpc-biosecurity.org]]></managingEditor><webmaster><![CDATA[webmaster@umpc-biosecurity.org]]></webmaster><lastBuildDate>Mon, 04 Jan 2010 15:11:55 GMT</lastBuildDate><generator>SiteExecutive v4.1</generator><item><title><![CDATA[NIAID, BARDA Award Anthrax Vaccine Contracts, Ebola/Marburg Contracts (10-06-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-10-06-niaidbardavaccontracts.html</link><description><![CDATA[Biosecurity Briefing: NIAID, BARDA awarded contracts to develop a next generation anthrax vaccine, as well as two contracts for development of a multivalent Ebola and Marburg vaccine.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-10-06-niaidbardavaccontracts.html</guid><pubDate>Tue, 07 Oct 2008 16:55:10 GMT</pubDate></item><item><title><![CDATA[HHS Takes Preparedness Measures for Anthrax; Requests Antibiotic Kit EUA for Postal Carriers, Liability Protection for Private Sector Businesses (10-06-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-10-06-hhsprepanthrax.html</link><description><![CDATA[Biosecurity Briefing: HHS announced that the dept. has called for 2 measures to prepare for an anthrax attack--issue kits containing antibiotics for postal workers and liability protections for private sector businesses engaged in some cntr. measures.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-10-06-hhsprepanthrax.html</guid><pubDate>Mon, 06 Oct 2008 22:02:38 GMT</pubDate></item><item><title><![CDATA[BARDA, NIAID Award Anthrax Monoclonal Antibody Contract; NIAID Awards Botulinum Antitoxin Contract (09-15-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-09-15-anthraxantibodybotulinumantitox.html</link><description><![CDATA[Biosecurity Briefing: On September 3, 2008, Emergent BioSolutions, Inc., announced that it had been awarded a $24.3 million contract to develop its anthrax monoclonal antibody AVP-21D9. The contract was awarded jointly by BARDA and NIAID.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-09-15-anthraxantibodybotulinumantitox.html</guid><pubDate>Tue, 16 Sep 2008 15:32:36 GMT</pubDate></item><item><title><![CDATA[India Imports Anthrax Vaccine, Bangladesh Expands Bird Flu Program (06-13-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/international_biosecurity/2008-06-13-indiaanthrxvacbangladesh.html</link><description><![CDATA[Biosecurity Briefing: The Times of India reported that a company in India has imported 200 doses of Biothrax, the only anthrax vaccine approved by the FDA. Xinhua News Agency reported that neighboring Bangladesh is expanding its bird flu prep programs.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/international_biosecurity/2008-06-13-indiaanthrxvacbangladesh.html</guid><pubDate>Fri, 13 Jun 2008 21:45:39 GMT</pubDate></item><item><title><![CDATA[FDA Approves Antimicrobial for Pediatric Inhalational Anthrax Exposure (05-16-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-05-16-fdaapprovantimicrobialpedathrax.html</link><description><![CDATA[Biosecurity Briefing: Drug Industry Daily news reports the FDA approved Levaquin (levofloxacin) for use in pediatric patients who have been exposed to Bacillus anthracis. This is the first and only pediatric indication for Levaquin.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-05-16-fdaapprovantimicrobialpedathrax.html</guid><pubDate>Fri, 16 May 2008 20:23:46 GMT</pubDate></item><item><title><![CDATA[HHS Requests Proposals for Next Anthrax Vaccine (03-07-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-03-07-hhsrfpanthraxvac.html</link><description><![CDATA[Biosecurity Briefing: CQ Politics reported that the HHS released a request for proposals (RFP) for development of a new anthrax vaccine. The RFP requires 25 million doses of a vaccine that can be administered in only three doses.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-03-07-hhsrfpanthraxvac.html</guid><pubDate>Mon, 10 Mar 2008 15:57:04 GMT</pubDate></item><item><title><![CDATA[House Committee Concerned About Timeline for Acquisition of Anthrax Countermeasures (09-14-2007)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/content/2007/2007-09-14-housecomtimeanthraxcounter.html</link><description><![CDATA[Biosecurity Briefing: The House Committee on Homeland Security expressed disappointment regarding the pace with which the agency has moved toward the development and procurement of a recombinant protective antigen anthrax vaccine.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/content/2007/2007-09-14-housecomtimeanthraxcounter.html</guid><pubDate>Fri, 14 Sep 2007 22:03:00 GMT</pubDate></item><item><title><![CDATA[Study Shows New Adjuvant, Nasal Spray Vaccine May Offer Protection against Anthrax (08-24-2007)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/content/2007/2007-08-24-studyshowsnewadjuvantprotectagainstanthrax.html</link><description><![CDATA[Biosecurity Briefing: According to a study in Infection and Immunity, anthrax vaccine with a new adjuvant administered nasally provided guinea pigs greater protection against lethal doses of anthrax than the standard vaccine administered by injection.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/content/2007/2007-08-24-studyshowsnewadjuvantprotectagainstanthrax.html</guid><pubDate>Fri, 24 Aug 2007 22:03:00 GMT</pubDate></item><item><title><![CDATA[Candidate Anthrax Treatment Receives Orphan Drug Designation (03-10-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-10-candidateanthraxtrtmtgetsor.html</link><description><![CDATA[Biosecurity Briefing: On March 6, Medarex, Inc. and PharmAthene, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to Valortim™ (MDX- 1303).]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-10-candidateanthraxtrtmtgetsor.html</guid><pubDate>Wed, 31 Jan 2007 17:22:30 GMT</pubDate></item><item><title><![CDATA[HHS Extends VaxGen's Deadline to Resolve Clinical Hold on Anthrax Vaccine (11-17-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-11-17-hhsvaxgendeadline.html</link><description><![CDATA[Biosecurity Briefing: VaxGen announced that the US Dept of Health and Human Services (HHS) has extended by more than a month the deadline for VaxGen to resolve the clinical hold placed on its anthrax vaccine trials by the Food and Drug Administration.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-11-17-hhsvaxgendeadline.html</guid><pubDate>Fri, 17 Nov 2006 20:11:00 GMT</pubDate></item><item><title><![CDATA[Delays in Anthrax Vaccine Delivery Raise Concerns about BioShield Process (08-18-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-08-18-anthraxvxdeliverydelays.html</link><description><![CDATA[Biosecurity Briefing: The San Jose, CA Mercury News reports recent concerns about delivery of a new anthrax vaccine being developed by VaxGen and funded by the Department of Health and Human Services (HHS).]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-08-18-anthraxvxdeliverydelays.html</guid><pubDate>Fri, 18 Aug 2006 17:22:00 GMT</pubDate></item><item><title><![CDATA[HHS Buys Additional Anthrax Therapeutic for the SNS (07-28-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-07-28-hhsbuysaddlanthxtherapforsns.html</link><description><![CDATA[Biosecurity Briefing: On July 28, HHS announced that it had awarded a $143,833,719 contract to Cangene Corporation (Cangene) for the purchase of 10,000 therapeutic courses of Anthrax Immune Globulin (AIG) for the Strategic National Stockpile (SNS).]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-07-28-hhsbuysaddlanthxtherapforsns.html</guid><pubDate>Fri, 28 Jul 2006 17:22:00 GMT</pubDate></item><item><title><![CDATA[HHS Purchases Anthrax Therapeutic for the SNS; Development of Additional Candidate Anthrax Therapeutics Continues (06-23-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-06-23-hhspurchasesanthraxtherapeuticforSNS.html</link><description><![CDATA[Biosecurity Briefing: On June 20, the U.S. Department of Health and Human Services (HHS) announced that it has exercised the option under its contract with Human Genome Sciences, Inc. (HGS) to purchase ABthraxTM for the Strategic National Stockpile (SNS).]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-06-23-hhspurchasesanthraxtherapeuticforSNS.html</guid><pubDate>Fri, 23 Jun 2006 17:22:00 GMT</pubDate></item><item><title><![CDATA[New Anthrax Vaccine with Improved Stability Sought (06-19-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-06-19-newnanthraxvaccinewithimprovedstabilitysought.html</link><description><![CDATA[Biosecurity Briefing: On June 12, Avecia Biotechnology announced that it had received a $3.9 million grant from the U.S. National Institute of Allergy and Infectious Diseases to develop an anthrax vaccine with "improved stability."]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-06-19-newnanthraxvaccinewithimprovedstabilitysought.html</guid><pubDate>Mon, 19 Jun 2006 17:22:00 GMT</pubDate></item><item><title><![CDATA[FDA Issues Warning to VaxGen Regarding its Anthrax Vaccine (03-31-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-31-fdaissueswarningtovaxgenreg.html</link><description><![CDATA[Biosecurity Briefing: On April 4, the USDA's Office of Compliance and Biologics Quality (OCBQ) made public a warning letter it sent to VaxGen, Inc. on March 24, 2006, regarding VaxGen's candidate anthrax vaccine (rPA102).]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-31-fdaissueswarningtovaxgenreg.html</guid><pubDate>Fri, 31 Mar 2006 17:22:00 GMT</pubDate></item><item><title><![CDATA[Pentagon Releases Report on Response to March 2005 Anthrax Incidents (03-31-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-31-pentagonreleasesreportonmar.html</link><description><![CDATA[Biosecurity Briefing: According to a March 24 Department of Defense (DoD) press release, the RAND Corporation delivered an assessment to the Pentagon on the department's response to three suspected anthrax incidents that occurred in March 2005.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-31-pentagonreleasesreportonmar.html</guid><pubDate>Fri, 31 Mar 2006 17:22:00 GMT</pubDate></item><item><title><![CDATA[VaxGen Responds to Concerns About its Anthrax Vaccine (03-24-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-24-vaxgenrespondstoconcernsabo.html</link><description><![CDATA[Biosecurity Briefing: On March 17, VaxGen responded to a recent Washington Post report that VaxGen has encountered problems with its anthrax vaccine, rPA102, that may delay its delivery to the government for the Strategic National Stockpile.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-24-vaxgenrespondstoconcernsabo.html</guid><pubDate>Fri, 24 Mar 2006 17:22:00 GMT</pubDate></item></channel></rss>
